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Vernicia fordii Hemsl. (V. fordii), also known as Aleurites fordii, is widely used in oriental 
medicine to treat wounds and infections. Diabetes is primarily caused by reduced secretion of insulin 
from pancreatic β-cells. Hence, the restoration of glucose-stimulated insulin secretion (GSIS) in the 
pancreas is effective therapy for type 2 diabetes. This study aimed to estimate the activity and 
mechanisms of V. fordii extract (VFE) as an insulin secretagogue and assess its potential as an 
antidiabetic agent. In pancreatic β-cells, VFE dramatically potentiated insulin release in a dose- & time-
response manner and under hyperglycemia compared to euglycemia condition. Interestingly, the 
insulinotropic role of VFE was blunted by diazoxide and nifedipine. VFE significantly increased 
glucose uptake and ATP production, and stimulated PKCα/MARCKS activation by intracellular Ca2+ 
influx. Orally administered VFE ameliorated hyperglycemia and improved insulin sensitivity in HFD-
fed mice, and reduced pancreatic islet size compared to that observed in HFD-fed mice. This study 
establishes that VFE has a strong insulinotropic effect and improves insulin sensitivity by increasing 
glucose uptake and PKCα activation via intracellular Ca2+ influx. Our study suggests that VFE could 
be potentially used for improving β-cell function and treating diabetes and metabolic diseases. 
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1-1. Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2DM) is the ubiquitous people suffering metabolic disease which 
has been denoted in considerable areas of the world including western countries, Asia, and Africa (Fig. 
1-1). T2DM accompanies lots of chronic and severe complications disturbing quality of life, such as 
cardiovascular disease (CVD), stroke, peripheral vascular disease like neuro- and retinopathy or End-
stage renal disease. The healthcare costs for T2DM patients have been continuously increased and 
became a big burden on individuals and society 1.  
T2DM, unlike type 1, is an acquired disease due to the lack of insulin action (Insulin resistance) 
with lower released insulin level (β-cell dysfunction) (Fig. 1-2), and is a progressive metabolic disease 
in which blood glucose continues to deteriorate even after the disease outbreak. T2DM is known to be 
caused by genetic factors or environmental such as a Westernization diet, sedentary lifestyle, and 
obesity 2. 
 
1-2. Glucose-stimulated insulin secretion 
In pancreatic β-cells, Glucose-stimulate insulin secretion (GSIS) is a chief insulin secretion 
system regulating the metabolic homeostasis of life. GSIS is led to the extracellular glucose elevation 
mediated glucose internalization via a glucose transporter. Internalized glucose participates in the 
oxidation system and intracellular ATP synthesis. Afterward, these changes induce blockage of the ATP 
sensitive K+ channel occurs to the membrane depolarization resulting in intracellular Ca2+ influx, and 
consequently, insulin secretion by exocytosis aroused (Fig. 1-3) 3. 
 
1-3. Natural products derived bioactive compounds treating diabetes  
Due to its’ diversity, the plant is a promising source of natural compounds that play a therapeutic 
role with lower risk in various diseases, and readily available 4. Approximately, half percent of the US 
FDA approved drugs were the phytomedicinal derivatives such as metformin, aspirin, etoposide, 
teniposide, morphine, camptothecin, and quinine 5. Furthermore, the tons of plants and derived 
bioactive-compounds have been detailed scientifically to be effective in treating T2DM, and studies 
have continued to search for highly active natural compounds for T2DM treatment (Fig. 1-4) 6. However, 
these plants that are traditionally used as antidiabetic agents, their usage in diabetes treatment is limited 
due to a lack of research and proper tools for searching the mechanism of action. Burns et al., have 
developed the easy and quick high-throughput screening tool using luciferase system for insulin 






Figure 1-1. Number of adults suffering type 2 diabetes mellitus in the world (20-79 years) 
 



















Figure 1-2. Major characteristics of pancreatic function in healthy vs diabetic individuals 
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Figure 1-3. Glucose-stimulated insulin secretion mechanism 
 















Figure 1-4. The characteristics of natural product improving pancreatic β-cell function and diabetes. 
 









Figure 1-5. Luminescent insulin reporter assay by inserting Gaussia luciferase to pancreatic β-cells 
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Ⅱ. Vernicia fordii extract stimulates insulin secretion in pancreatic β-cells 
2-1. Introduction 
Diabetes mellitus (DM), defined to prolonged hyperglycemia, is the most prevalent metabolic 
disease. DM, classified as type 1 or 2 (T1DM and T2DM), are innate and acquired disorders associated 
with pancreatic insulin secretion 8. A major complication of diabetes is chronic hyperglycemia as a 
result of reduced insulin secretion from pancreatic β-cells 9. In addition to reduced insulin secretion, 
peripheral tissues, such as liver, muscle, and fat tissues, fail to respond to insulin; this phenomenon is 
termed insulin resistance 8. Impaired insulin secretion is a pathophysiological T2DM characteristic and 
causes diabetic vascular comorbidities (i.e.; neuropathy, retinopathy, and nephropathy) 10. Therefore, 
restoring insulin secretion could be an effective strategy for treating hyperglycemia and diabetic 
complications. 
Currently, various insulin-releasing drugs such as sulfonylureas, glucagon-like peptide (GLP-1) 
receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors, were prescribed to T2DM patients 
have been prescribed limitedly owing to a series of severe side effects such as hypoglycemia, 
cardiovascular disease (CVD), and certain cancers 11. Thus, antidiabetic drug development strategies 
should focus on controlling glucose homeostasis, thereby improving safety despite extended use. 
In normal pancreatic β-cells, glucose metabolism is an essential process coupled to GSIS 12. The 
transported glucose via glucose transporters is metabolically processed to generate the intracellular ATP. 
Increased level of ATP results in the closure of ATP-sensitive potassium ion channels (KATP). KATP 
channel blockade leads to membrane depolarization and subsequent opening of L-type voltage-
dependent calcium channels (L-VDCCs), allowing Ca2+ influx, which stimulates insulin release. After 
the initial glucose-stimulated insulin secretion (first-phase), the altered intracellular Ca2+ level ([Ca2+]i) 
becomes a source for the lasting, intense insulin release (second-phase) from β-cells 12. Among the 
second-phase insulin secretion associated signals, protein kinase C (PKC) roles critically in GSIS. 
Previous study identified that the activation of multiple PKC isoforms is closely associated with GSIS 
in β-cells. Particularly, glucose-induced [Ca2+]i activates PKC, which phosphorylates various substrates 
involved in the second-phase release of insulin in β-cells 13. In addition, this process potentiates 
susceptibility to Ca2+ response in exocytosis machinery, promoting the net released insulin in response 
to a given Ca2+ level 14. 
Natural products are invaluable for the treatment of diseases 15. Drugs sourced from natural 
products are considered safer, cheaper, easier to obtain and sometimes more effective for specific 
diseases than purely synthetic drugs. Particularly, active molecules from plants have been investigated 
as insulin secretagogues, and their role in the glycemic control of GSIS is being studied 16. 
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Vernicia fordii Hemsl. (V. fordii), also known as Aleurites fordii, is ubiquitously found in Korea 
and China. The leaves and fruit are used as an oriental treatment 17. Recent studies identified the antiviral 
and anti-cancer effects of the active compounds derived from V. fordii leaf extracts 18, 19. In particular, 
among the antiviral effects of V. fordii, the leaf extract and its refined derivatives act as an effective 
Epstein-Barr virus (EBV) lytic inducers in the gastric carcinoma cells (EBV-positive) via the PKC/MEK 
pathways 20. However, the biological effects of V. fordii on glycemic control and insulin release have 
not been examined. Here, we demonstrated that the V. fordii leaf extract (VFE) had a strong 
insulinotropic effect in pancreatic β-cells and ameliorated insulin resistance. These findings reveal that 













2-2. Materials and Methods 
Plant materials 
Mass cultivated leaves parts of Vernicia fordii (V. fordii) were collected at Jeju-do, Republic of 
Korea, in June 2011 and identified by Dr. Chan-Soo Kim (Warm Temperature Forest Research Center, 
Korea Forest Research Institute), and a voucher specimen (KRIB 0000463) was deposited at the Plant 
Extract Bank (https://portal.kribb.re.kr/kpeb/) of KRIBB in Daejeon, Korea. After harvesting, the leaves 
were immediately freeze-dried (CleanVac 8 Hanil Science Medical, Korea), pulverized (tube mill, IKA, 
Germany) and stored at -40 ℃ until analysis. 
Sample extraction and isolation 
The leaves of V. fordii (343.6 g) were extracted in 100% methanol at room temperature for 24 
h. The methanol extract of leaves of V. fordii (53.18 g, yield: 15.5 %, TVFE) was fractionated into five 
fractions using MPLC (Spot Prep II 250 instrument, Armen, France), which has assembled a reverse-
phase silica gel column (YMC-Pack ODS-AQ-HG, 10 μm, 250×20 mm) under the conditions of a 
mobile phase in which water (A) and methanol (B) were mixed (0-10 min 10% B, 10-60 min 10-100% 
B, 60-90 min 100% B) and flow rate of 20 ml/min (Fig. 8. and 9.). For further bioactivity-guided 
fractionation, as a result of looking at increased insulin release in MIN6 cell for the separated five 
fractions, the highest insulin release was found in fraction 5 (VF Fr.5; VFE) (Fig. 2.B.). Based on this 
result, fractionation was continued for VFE, which was fractionated into seven fractions using the same 
equipment and columns from VFE, but different mobile phase conditions (A: water, B: MeOH, 0-5 min 
60% B, 5-60 min 60-100% B, 60-100 min 100% B) (Fig. 8.-10.). The VF Fr. 5-3 (608 mg) was 
fractionated into 14 fractions using Gilson PLC 2250 Purification System (WI, USA) assembled a 
reversed-phase silica gel column (INNO C18, 5 μm, 250×20 mm) under the conditions of a mobile 
phase in which water with 0.1% trifluoroacetic acid (A) and acetonitrile (B) were mixed (0-5 min 75% 
B, 5-60 min 75-85% B, 61-70 min 100% B) and flow rate of 17 ml/min (Fig. 8.-13.). The VFL Fr. 5-3-
9 (94.9 mg) was isolated for 12-O-hexadecanoyl-16-hydroxyphorbol-13-acetate (HHPA, 9.7 mg) using 
Gilson PLC 2250 Purification System assembled a reversed-phase silica gel column (synergy polar, 4 
μm, 250×20 mm) under the conditions of a mobile phase in which water with 0.1% trifluoroacetic acid 
(A) and acetonitrile (B) were mixed (0-5 min 60% B, 5-60 min 60-70% B, 61-70 min 100% B) and 
flow rate of 15 ml/min (Fig. 8.-16.). The yield of the HHPA obtained was 0.21% from MeOH extract 
determined by using ultra-performance liquid chromatography (UPLC) charged with photodiode array 
(PDA) and charged aerosol detector (CAD) (Fig. 8.-17.). Based on UPLC-CAD analysis, the purity of 
HHPA was more than 97.0% (Fig. 8.-18.). HHPA was tentatively identified by UV, MS and MS/MS 
spectra, and HRMS of HHPA compared of the previous literature data, including the UV, m/z values, 
MS fragments, and molecular formulae data 21 (Fig. 7. and Table 1.). The main compound (9.7 mg) 
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were dissolved in 600 µl chloroform-d (Cambridge Isotope Laboratories, MA, USA) as a solvent, with 
tetramethylsilane (TMS) as an internal standard, and then measured to NMR (Bruker AVANCE III HD 
700 MHz, MA, USA). Chemical shifts were reported in ppm (δ) and J in Hz values. HHPA were 
identified by comparisons of chemical shifts previously reported (Fig. 19.-20., and Table 2-3) 20-22. 
Cell Culture  
The mouse pancreatic β‐cell line MIN6 was gifted from Prof. Jun‐Ichi Miyazaki (Osaka 
University, Japan). Unless otherwise indicated, entire chemical materials were supplied from Sigma-
Aldrich (MO, USA) for cell culture. Primary islet was isolated using the methods which was published 
in previous report (Hwang et al., 2018). MIN6 cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) and the isolated islets were cultured in RPMI-1640 medium. Both medium was 
containing with 10% fetal bovine serum (Gemini Bio-products, CA, USA), 55 µM β-mercaptoethanol, 
2 mM L-glutamine, 1% penicillin/streptomycin (Thermo Fisher Scientific, MA, USA). Cells were 
cultured at 37 ℃ in a humidified air containing 95% air and 5% CO2. 
Insulin secretion assay 
Proinsulin-NanoLuc in pLX304 plasmid for Luminescent reporter of insulin secretion assay was 
purchased from Addgene (MA, USA). Proinsulin-Gaussia luciferase analysis was performed using the 
methods which were previously reported (Burns et al., 2015). Briefly, proinsulin-Gaussia luciferase 
plasmid-introduced MIN6 cells and incubation in 96-well scale for 72 h. Prior to luciferase analysis 
experiments, MIN6 cells were rinsed with PBS and supplemented 2.8 mM glucose containing Krebs 
Ringer bicarbonate buffer (KRB). After 1 h, MIN6 cells were applied with KRB containing different 
doses of chemicals with 2.8 or 16.7 mM glucose for another 1 h. Size-matched primary islets were 
applied to the indicated concentration of chemicals in KRB with 2.8 or 16.7 mM glucose for additional 
1 h. As the vehicle, DMSO was treated. The amount of insulin in each supernatant from MIN6 and 
pancreatic islets were quantified to coelenterazine substrate addition (Nanolight Tech., AZ, USA) and 
ELISA (Alpco Diagnostics, NH, USA), respectively. All steps were performed in a 37 °C, 5% CO2 
incubator.  
In vitro cytotoxicity test 
For analyzing the cytotoxic effect of VFE on MIN6 cells, we carried out the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) test former reported 23. 
Glucose uptake measurement 
Uptake glucose levels were measured in MIN6 cells with a 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-
4-yl)amino]-2-deoxy-D-glucose (2-NBDG, Cayman Chemical). MIN6 cells were rinsed and 
maintained for 1 h at 37 °C in glucose-free KRB. Subsequently, 600 μM 2-NBDG has applied to the 
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cells with VFE for 20 min at 37 °C. To eliminate the debris or background fluorescence, the cells were 
then rinsed two times with free glucose KRB and added Lysis buffer [(mM) 150 NaCl, 50 Tris-HCl (pH 
8.0), 5 EDTA, 1% Triton X-100, 0.1% SDS, with 0.5% Na-deoxycholate] to detect the fluorescent 
intensity using a microplate reader (Tecan Trading) at 485/535 nm. Fluorescence intensity was 
normalized by the protein amounts per each well after background subtraction. 
Mitochondrial oxygen consumption rate (OCR) 
The effect of VFE on mitochondrial function was assessed from MIN6 cells in XFe24 
microplates (Seahorse Bioscience, MA, USA). The cells were treated with VFE in 16.7 mM glucose 
KRB for 1 h following 2.8 mM glucose containing KRB incubation for 1 h. Then, cells were rinsed 
with extracellular flux modified medium (Seahorse Bioscience). Then the plate was performed to a 
Seahorse Bioscience XFe24 extracellular flux analyzer, and Oligomycin (2 µM), FCCP (3 µM), 
Rotenone (1 µM) were consequently applied to evaluate the OCR for 2 h in MIN6 cells. Entire 
chemicals were purchased from Sigma-Aldrich. 
Intracellular Ca2+ measurement 
PBS rinsed MIN6 cells were stained using 10 μM Fura-2AM (fura-2-acetoxymethyl ester; 
Invitrogen, CA, USA) in glucose-free KRB during 30 min. The cells were then rinsed again by glucose-
free KRB and loaded onto a microscope holder. The chemicals were applied to the cells on image 
screened by the mixture. The excitation was detected by a fluorimeter to monitor Fura-2AM at 
difference fluorescence 340 / 380 nm simultaneously using Olympus IX81 microscope (Olympus Corp., 
Japan). 
Western blot analysis 
MIN6 cells stimulated by VFE or tissues from VFE-treated mice were treated with RIPA buffer 
(Thermo Fisher). Quantified protein was applied to SDS-PAGE and transferred to nitrocellulose 
membrane (GE healthcare, CA, USA). 5% (w/v) bovine serum albumin was used for the blocking the 
membrane and the membrane was incubated with primary antibodies overnight at 4 ℃. Anti-Phospho-
PKC Substrate Motif [(R/K)XpSX(R/K)] MultiMab™ rabbit mAb mix, anti-phospho-MARCKS 
(S152/156), anti-phospho-Akt (S473), anti-Akt, anti-phospho-CREB (S133), anti-CREB, anti-β-Actin, 
and anti-HSP90 antibodies were purchased from Cell Signaling (MA, USA). Anti-phospho-PKCα 
(S657), anti-PKCα, anti-MARCKS antibodies were purchased from Santa Cruz Biotechnology (TX, 
USA). We assessed the intensity of band by ImageJ (NIH, MD, USA).  
Gene expression analysis 
Extraction of RNA as of cells and tissues was carried out using Trizol (Invitrogen, CA, USA). 
The complementary DNA which was synthesized by reverse-transcription kit (ABI; Invitrogen) was 
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used to quantitative PCR with SYBR dye (ABI9300; Thermofisher). Relative mRNA expressions 
estimated by the ∆∆-Ct equation were divided to ribosomal Protein L32 (Rpl32) expressions. Primers 
for each gene were summarized in the Table 4. 
Animal experiments 
Entire in vivo experiments were followed the Ulsan National Institute of Science and 
Technology’s Institutional Animal Care and Use Committee (UNISTIACUC-19-04). Wild C57BL/6J 
mice were cared in the pathogen-free facility under 12-h light/dark cycles. Standard diet with water was 
given to ad libitum. For 16 h, C57BL/6J male mice (8‐week‐old) were restricted to diets. Mice were 
orally injected 3 g/kg D‐glucose after 30 min 10, 20, or 50 mg/kg doses of VFE, and 30 mg/kg dose of 
Glbenclamide, or vehicle oral administration. The monitoring of blood glucose was performed by tail 
blood using glucometer (All Medicus, Korea), and Mouse Ultrasensitive Insulin ELISA (ALPCO) kit 
was used for serum insulin detection. 
For analyzing metabolic effects of VFE, the male C57BL/6J mice (8-week-old) were received 
high-fat diets (HFD) (60% kcal fat, D12492, Research Diets Inc., NJ, USA) during 4-weeks and orally 
supplied 20 or 50 mg/kg VFE, and 30 mg/kg Glb, or vehicle for additional 6-weeks with HFD. Body 
and intake food weights were checked in every week. For oral glucose tolerance test (OGTT), mice 
were restricted food for 16 h before 3 g/kg d-glucose injection. The mice restricted food for 6 h were 
received 0.75 U/kg insulin intraperitoneal injection for intraperitoneal insulin tolerance test (IPGTT). 
The blood glucose were monitored by glucometer (All Medicus). HOMA-IR was acquired following 
the previous report 24. QUICKI was acquired using the equation (QUICKI = 1 / [log(FI[μU/ml]) + 
log(FG[mg/dl])]). Serum insulin (ALPCO) and TG (Cayman chemical) were determined by ELISA. 
Histological analysis  
Whole pancreas is collected and fixed using 4 % paraformaldehyde overnight at RT. The fixed 
pancreas was subsequently dehydrated and embedded in paraffin. The paraffin blocks were sectioned 
with a DM6000B microtome (Leica, Germany). To dewax the sections, each tissue section was exposed 
to the sequential steps of xylene and ethanol washes. Tissues were counterstained with H&E to represent 
pancreatic islet structures.  
Statistical analysis 
Data are shown as means + S.E.M. The estimated statistical significance using unpaired t‐test 
was compared within paired condition. The comparison between more than two conditions was used a 
one‐way ANOVA. Dunnett’s post hoc test was tried multiple comparisons. GraphPad Prism 8.0 





V. fordii extract (VFE) increases insulin secretion in hyperglycemic conditions 
To search the effect of V. fordii on the function in pancreatic -cells, we performed a luminescent 
reporter assay using Proinsulin-Gaussia luciferase construct inserted MIN6 cells. In the low glucose 
condition (2.8 mM glucose; LG), TVFE, the V. fordii leaf methanol extract, did not increase insulin 
secretion (0.3 μg/ml; 1.11 ± 0.36, 1.25 μg/ml; 1.15 ± 0.11, and 5 μg/ml; 1.20 ± 0.19 fold increases) (Fig. 
1.A.). In contrast, under high glucose condition (16.7 mM glucose; HG) TVFE resulted in significant 
increase in insulin secretion dose-dependently (0.3 μg/ml; 2.06 ± 0.03, 1.25 μg/ml; 3.44 ± 0.16, and 5 
μg/ml; 6.05 ± 0.29 fold increases). In addition, insulin release stimulated by TVFE was similar to that 
of 12-O-Tetradecanoylphorbol-13-acetate (PMA) which reportedly increases insulin secretion in 
pancreatic β-cells 13. Next, we fractionated TVFE, producing VFE as the most effective fraction in 
stimulating insulin secretion in MIN6 cells (Fig. 1.B.). MIN6 cells with VFE incubation potentiated 
insulin release in a dose-dependent manner in HG (0.1 μg/ml; 4.44 ± 0.23, 0.3 μg/ml; 6.29 ± 0.38, 1 
μg/ml; 7.90 ± 0.55, and 500 nM PMA; 9.11 ± 0.10 fold increases) (Fig. 1.C.). Besides, VFE stimulated 
insulin release, which was significant starting from 15 min after treatment and reached a maximum 1 h 
after treatment in MIN6 cells (Fig. 1.D.). Consistent with the results in MIN6 cells, VFE significantly 
increased insulin release in a dose-responsibly in murine primary islets; this effect on insulin release 
was more dramatic under HG conditions (0.1 μg/ml; 3.41 ± 0.42, 0.3 μg/ml; 5.25 ± 0.31, 1.0 μg/ml; 
10.18 ± 0.24 %, 500 nM PMA; 16.61 ± 0.56 fold increases) (Fig. 1.E.). To validate the cytotoxic effect 
of TVFE or VFE in the MIN6 cells, we performed an MTT assay. Cell viability was not altered at 
concentrations <20 μg/ml of each chemical, indicating that TVFE and VFE potentiate insulin release 
without inducing cytotoxicity (Fig. 1.F.), Thus, these data suggest that VFE potentiates GSIS in 
pancreatic β-cells. 
VFE increases intracellular Ca2+ influx in MIN6 cells 
The rise of intracellular Ca2+ level ([Ca2+]i) is essential for GSIS via activation of exocytosis 12. 
As VFE stimulated insulin secretion in HG compared to LG, we hypothesized that VFE-induced insulin 
secretion is mediated by increased [Ca2+]i. We measured the acute Ca2+ transition after VFE treatment 
during Fura-2AM loading in MIN6 cells. As shown in Fig. 2.A. and 2.B., a substantial elevation in the 
[Ca2+]i was monitored following VFE treatment in a dose-dependent manner. Glibenclamide (Glb), a 
specific inhibitor of KATP sulfonylurea receptor 1 channels (Sur1-Kir6.2) that is used either as 
monotherapy or in combination with biguanides in the management of T2DM was used as a positive 
control to increase [Ca2+]i 25.  
Next, we determined whether the sources of Ca2+ was extra- or intracellular. In the absence of 
extracellular Ca2+ ([Ca2+]e), the use of calcium-free KRB buffer resulted in a dramatic reduction in VFE-
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induced GSIS compared with that observed on using Ca2+ containing KRB (Fig. 2.C.). These results 
propose that VFE on insulin release is largely on account of the [Ca2+]e influx in pancreatic β-cells. 
VFE activates PKCα-MARCKS for insulin secretion.  
It is established that increased [Ca2+]i triggers PKCα activation, which is a key mechanism for 
inducing GSIS in pancreatic β-cells 13, 26. Thus, we tested whether VFE activates PKC in pancreatic -
cells. As shown in Fig. 3.A. and 3.B., VFE dramatically increased PKC activation in dose- and time-
response manner, as confirmed by western blotting with PKC substrate antibody or phospho-specific 
PKCα antibody. In addition, we confirmed that VFE activated myristoylated alanine-rich C-kinase 
substrate (MARCKS), the major PKC substrate that is involved in insulin secretion by actin 
rearrangement in pancreatic β-cells (Fig. 3.A. and 3.B.) 27. The specific inhibitor of PKC, Gö6983 
significantly inhibited the activation of both PKCα and MARCKS (Fig. 3.C.), and insulin secretion (Fig. 
3.D.). Beside increased [Ca2+]i, it is reported that PKCα can be activated by phospholipase C (PLC) 
stimulation 26. Thus, we checked whether VFE alternatively activates PKCα via PLC activation. As 
shown in Fig. 3.E., the insulinotropic effect of VFE did not be changed by a specific inhibitor of PLC, 
U73122 in MIN6 cells, indicating that VFE stimulates insulin secretion mainly through Ca2+-induced 
PKCα activation.  
Thereafter, we investigated whether the disruption of [Ca2+]e influx or KATP activation regulates 
PKCα activation and insulin release in pancreatic β-cells. It has been well studied that [Ca2+]e inflow 
through either L-VDCCs or KATP is crucial to insulin secretion 12. The inhibition of L-VDCCs by 
nifedipine, a specific L-VDCC blocker, suppressed VFE-induced PKCα activation and insulin secretion, 
indicating that the [Ca2+]e inflow via L-VDCCs by VFE increases insulin exocytosis (Fig. 3.F. and 3.G.). 
Furthermore, the selective KATP activator diazoxide reduced PKCα activation and insulinotropic effect 
of VFE (Fig. 3.H. and 3.I.). Thus, these data strongly suggest that [Ca2+]e influx via L-VDCCs and KATP 
channels by VFE treatment is critical for insulin exocytosis via Ca2+-dependent PKCα activation in the 
pancreatic β-cells. 
VFE promotes glucose uptake and mitochondrial ATP production 
Glucose transport and metabolism in pancreatic β-cells are essential process coupled to GSIS 
by the regulation of KATP activity 12. Thus, we investigated the effect of VFE on GSIS by measuring 
intracellular glucose abundance and mitochondrial ATP production. First, glucose uptake estimated by 
2-NBDG revealed that VFE dramatically enhanced glucose transport into MIN6 cells in a dose-
dependent manner (Fig. 4.A.). In murine pancreatic β-cells, the major glucose transporter is slc2a2 (also 
known as glucose transporter-2; Glut2) 28, therefore, we analyzed the expression of Glut2 in the presence 
with VFE. As shown in Fig. 4.B., VFE rose notably the Glut2 expresion. In addition to Glut2, the 
expression of Pcx (Pyruvate carboxylase; PC) and Ins1 (proinsulin gene 1; Ins1) which have prominent 
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roles in GSIS also increased after treatment with VFE (Fig. 4.B.). Reportedly, the expression of Glut2, 
PC, and Ins1 are tightly regulated by the cAMP response element-binding protein (CREB) activity 29. 
As shown in Fig. 4.C., the activation of CREB by VFE was dose-dependent, indicating that VFE 
enhances CREB activity and CREB-mediated gene expression to promote glucose uptake in pancreatic 
β-cells.  
Next, we estimated the effect of VFE on mitochondrial respiration using a seahorse cellular 
bioenergetic analyzer. Oligomycin A (a complex V inhibitor), carbonyl cyanide-4-
trifluoromethoxyphenylhydrazone (FCCP) (an oxidative phosphorylation uncoupler), and rotenone (a 
complex I inhibitor) were sequentially added to evaluate the effect of VFE on the electron transport 
chain function. Pre-treatment with VFE dramatically increased the oxygen consumption rate (OCR) in 
a dose-response manner (Fig. 4.D.). The basal respiratory rate and the FCCP-treated maximal capacity 
of mitochondrial respiration were both increased by VFE (Fig. 4.E.). Finally, the increased OCR by 
VFE resulted in increased ATP generation in MIN6 cells dose-dependently (Fig. 4.F.). These data 
support the notion that the boosted mitochondrial function including enlarged glucose uptake and ATP 
generation, is a vital mechanism for VFE-stimulated insulin secretion in MIN6 cells.  
VFE reduces blood glucose level through insulin release promotion in vivo  
To explore the insulinotropic effect of VFE in vivo, we performed the VFE pre-treatment to male 
C57BL/6J mice (8-week-old) in various doses via oral injection followed by glucose administration and 
monitoring of blood glucose levels. The dose-dependent glucose-lowering effect of VFE was observed 
at 30 min after glucose administration during an oral glucose tolerance test (OGTT) (Fig. 5.A.). VFE-
injected mice showed a remarkable glucose decrease in blood in comparison to vehicle-treated mice 
(VFE 10 mg/kg, 19.9 ± 4.1 %; 20 mg/kg, 31.3 ± 1.7 %; 50 mg/kg, 38.6 ± 1.1 % reduction). Glb 
significantly reduced blood glucose levels (49.8 ± 2.2 % reduction), as reported 25. Despite neither VFE 
nor Glb altering the body weight (Fig. 5.B.), the VFE induced blood glucose reduction was attended 
with an increased level of plasma insulin after glucose administration (Fig. 5.C.). These results show 
that the VFE glucose-lowering effect is the result of promoted insulin secretion in pancreatic β-cells. 
VFE improves insulin sensitivity in HFD-induced diabetic mice 
Impaired insulin secretion is a critical pathophysiologic character of T2DM and the restoration 
of insulin secretion is an effective therapeutic options for diabetic complications 30. Since observing the 
promising insulinotropic effect of VFE with lowering blood glucose levels, we investigated whether 
VFE exerts antidiabetic properties in vivo. We orally injected VFE at indicated doses for additional 6-
weeks in the same diet after feeding a high fat diet (HFD) to wild-type C57BL/6J mice for 4-weeks. As 
shown in Fig. 6.A., compared with normal chow diet (NCD)-fed mice, HFD-fed mice exhibited 
substantial bodyweight gain. However, either VFE or Glb did not change the bodyweight or food intake 
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compared with vehicle treatment in HFD-fed mice (Fig 6.A. and 6.B.). Surprisingly, VFE administration 
for 5-weeks dramatically reduced fasting blood glucose levels, as did Glb, indicating that VFE has a 
potent hypoglycemic effect (Fig. 6.C.). 
After 6-weeks’ oral administration of VFE in HFD-fed mice, we performed an OGTT and IPITT. 
VFE dramatically alleviated the glucose intolerance and insulin resistance of HFD-fed mice and 
improved the fasting glucose levels in a dose-dependent manner (Fig. 6.D. and 6.E.). Control mice that 
supplied vehicle only had hyperinsulinemia, but VFE substantially lowered the fasting insulin levels in 
these mice (Fig. 6.F.). Decreased levels of HOMA-IR and increased levels of QUICKI clearly showed 
an improvement of insulin sensitivity following treatment with VFE (Fig. 6.G. and 6.H.). In addition, 
serum triglyceride (TG) levels remarkably decreased in VFE-treated mice, suggesting that VFE 
ameliorates insulin sensitivity in the fat tissue of VFE-treated mice (Fig. 6.I.). 
In addition, the major glucose-consuming peripheral tissues, such as liver and muscle exhibited 
activation of AKT which may indicate the glucose clearance effect on VFE fed mice compared with the 
diabetic control (Fig. 6.J.). Pancreatic islet expansion, especially β-cell mass, is well established in long-
term HFD feeding studies 31, 32. As shown in Fig. 6.K., H&E staining of the pancreas revealed that HFD 
dramatically increased β-cell mass compared to NCD, and VFE significantly reduced the size of 
pancreatic islets compared to HFD-fed group (Fig. 6.K.). These data suggest that VFE improves insulin 
sensitivity and prevents diabetic progression.  
Analysis of the major constituents of V. fordii leaves 
To isolate and identify the compounds of the V. fordii for increase in insulin release, a 
preliminary literature review and bioassay-guided fractionation were performed. A methanol extract 
was prepared from the leaves of V. fordii (TVFE) and was divided into 5 fractions (VF1–5) using MPLC. 
VF fraction 5 (VFE) showed significantly higher activity than the other fractions (Fig. 1.B.). Bioassay-
guided fractionation of the extract afforded a more active TVFE and VFE containing a variety of tigliane 
diterpene esters, as revealed by ultraperformance liquid chromatography quadrupole time-of-flight 
mass spectrometry (UPLC-QToF-MS) analysis (Fig. 7.A.). Searching the mass to charge ratios (m/z) of 
precursor ion using a published MS results-based approach and LCMS-guided isolation, led to the 
separation of four structurally unique tigliane diterpene esters. The exact molecular ions of the four 
peaks were 689 [M–H]–, 705 [M–H]–, 673 [M–H]–, and 643 [M–H]– (Table. 1). The most active 
fractions 5-3 and 5-3-9 which were divided from VFE using the prep-HPLC, were screened insulin 
secretion effect in MIN6 cells for searching the effective compounds (Fig. 11. and 14.). The compounds 
were discovered by comparing the spectroscopic data, including 1D-NMR, HRMS, calculated mass, 
error ppm, and chemical formula, with those previous reported 20, 22. Finally, we identified four 



















Impaired insulin production is a typical feature of T2DM. Controlling postprandial blood 
glucose levels by either insulin analogs or endogenous insulin-releasing molecules is an effective 
treatment for T2DM. However, hypoglycemic control through insulin analogs may increase the risk of 
developing diseases, such as bacterial infection, insulin autoimmune syndrome (IAS), or Hirata's 
disease 33. Therefore, regulation of blood glucose levels through enhanced endogenous insulin secretion 
is a more effective and safer therapy for the treatment of T2DM. Although insulin secretagogues such 
as sulfonylurea are broadly prescribed to promote insulin secretion in T2DM patients, continuous drug 
treatments are restricted due to side effects, for instance hypoglycemia, weight gain, and CVD 11. Thus, 
the development of novel insulin secretagogues has been focused on characterizing natural compounds. 
It has been reported that V. fordii is widely used as a suppressing viral infection and cancer progression 
in China 19, 34. Despite the identification of numerous phytochemicals of V. fordii, there is no evidence 
that they regulate insulin secretion and systemic insulin sensitivity. In this study, we illuminated that 
VFE has a potent role in pancreatic β-cells for insulin production in vitro and in vivo. These effects of 
VFE contribute to improvement in glucose tolerance and insulin action in a mouse model of diabetes.  
Insulin is secreted from pancreatic β-cells to the biphasic process 12. After elevation of glucose 
level, a transient increase in insulin occurs (first-phase secretion; within 15 min of glucose stimulation). 
Thereafter, the second-phase secretion follows, presumably due to a metabolic amplification pathway 
involving increased [Ca2+]i35. We showed that VFE regulates first- and second-phase secretion of insulin 
in MIN6 cells in this study. VFE dramatically increased [Ca2+]i within 2 min and insulin secretion was 
significantly increased within 15 min after VFE application (Fig. 1.D.). In addition, VFE-induced 
insulin secretion was amplified by Ca2+-dependent PKCα activation, which performs a staple part in 
second-phase insulin release in pancreatic β-cells (Fig. 3.A. and 3.B.). Reportedly, only fuel such as 
glucose can lead to second-phase insulin secretion through amplifying pathway, and it has been known 
that non-metabolized stimuli can cause to only first-phase insulin secretion 12. We demonstrated that 
VFE potentiates glucose uptake in pancreatic β-cells, implying that VFE modulates second-phase 
insulin secretion which is a glucose-dependent process. 
With extended purification analysis of VFE, we identified four compounds; 12-O-
hexadecanoyl-16-hydroxyphorbol-13-acetate (HHPA), 12-O-hexadecanoyl-7-oxo-5-ene-16-
hydroxyphorbol-13-acetate, 12-O-hexadecanoyl-4-deoxy-4α-16-hydroxyphorbol-13-acetate, and 12-
O-hexadecanoyl-phorbol-13-acetate as the bioactive constituents to stimulate GSIS in MIN6 cells (Fig. 
8.A. and 8.B.). Among them, HHPA exhibited the strongest effect on GSIS, which is structurally 
comparable to PMA, but is non-toxic (Fig. 21.-22.). Although HHPA is a PMA analog, it is possible 
that HHPA has different modes of action in GSIS than PMA. First, PMA is reported to activate PKCα 
to stimulate insulin secretion 36. However, the enhanced secretion by PMA did not alter glucose 
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metabolism, KATP activity, or [Ca2+]e influx 37. Our results strongly suggest that VFE upregulates the 
mitochondrial function through increased glucose uptake and increases Ca2+ influx in MIN6 cells (Fig. 
2.A. and 2.B.). In addition, we demonstrate that KATP inhibition due to ATP augmentation stimulated 
by VFE is an important mechanism for insulin secretion in MIN6 cells (Fig. 3.H. and 4.F.). Secondly, 
it is reported that staurosporine, a potent PKC inhibitor, completely suppressed PMA-induced insulin 
secretion 27. However, it could partially block GSIS as well, suggesting that staurosporine directly 
inhibits PKC, and alternative pathways could be involved in GSIS 38. Thirdly, besides [Ca2+]i, DAG 
which is produced by PLC, is involved in the activation of PKCα. As PMA can mimic DAG to induce 
insulin secretion in pancreatic β-cells, we tested the effect of PLC on VFE-mediated insulin secretion. 
However, the selective PLC inhibition did not alter VFE-induced insulin release. These results represent 
that the [Ca2+]i/PKCα axis not DAG, is the main target mechanism of VFE (Fig. 3.E.). 
In pancreatic β-cells, GSIS is regulated by several key genes, such as Glut2, Ins1, and PC. A lack of 
glucose transporter has been reported in murine T2DM models and human T2DM patients, and its 
deficiency in the pancreas resulted in a loss of GSIS, leading to severe hyperglycemia 39. Insulin 
hormone encoding Ins1 gene plays essentially in insulin biosynthesis and insulin production 40. Previous 
results have shown that chronical high glucose exposure to β-cells is related to blunted precursor insulin 
biosynthesis and lower Ins1 gene expression level 41. Pyruvate carboxylase (PC), a key enzyme of 
tricarboxylic acid (TCA) cycle in mitochondria, is abundantly expressed in β-cells. It is suggested that 
in pancreatic β-cells, the PC pathway plays an important role in pyruvate metabolism, insulin release 
and cell proliferation 42. Thus, the alteration of these gene expressions in pancreatic -cells is a hallmark 
of T2DM. Similar to these results, we checked that VFE rose the Glut2, Ins1, and PC expressions 
coupled with glucose-dependent CREB activation (Fig. 4C). and mitochondrial function (Fig. 4.D.-4.F.). 
The elevation of these glucose-regulated transcripts in cells by VFE treatment mean to remarkable 
glucose responsiveness of the β-cells that might be a key aspects treating diabetes. It has been known 
that fuel-dependent CREB activation stimulates the expression of pancreatic β-cell-specific genes 29, 
suggesting that VFE might promote the expression of those genes by glucose-induced CREB activation. 
Since it was not determined in this study, further investigations are necessary for determining the 









Current study, we proved that the beneficial effects of VFE on insulin sensitivity, thereby relieving 
metabolic diseases by controlling glucose metabolism with the GSIS. Furthermore, oral VFE 
administration improved glucose tolerance and insulin sensitivity in peripheral tissues, such as the liver 
and muscle, which predominate glucose metabolism participation. Although, the mechanism of VFE-
stimulated glucose uptake in pancreatic β-cells remains to be elucidated, our findings clearly 
demonstrate the metabolically beneficial effects of VFE and indicate its potential as a candidate for 

















Figure 1. V. Fordii extract (VFE) increases insulin secretion in MIN6 cells and Pancreatic islet.  
(A) TVFE on insulin release at low (2.8 mM) / high (16.7 mM) glucose dose-dependently in proinsulin-
Gaussia luciferase-introduced MIN6 cells.  
(B) Analysis of insulin secretion from MIN6 cells stimulated with 0.3 and 1 mg/ml of TVFE- 
subfractions in high glucose condition.  
(C) VFE on the insulin release in low and high glucose conditions dose-responsibly in proinsulin-
Gaussia luciferase-introduced MIN6 cells (n=3).  
(D) Time-dependent effect of VFE (1 mg/ml) on luminescent insulin secretion in low / high glucose in 
MIN6 cells.  
(E) The released insulin by VFE in low / high glucose in isolated pancreatic islet dose-dependently.  
(F) Dose-response effect of TVFE and VFE for 24 h incubation on MIN6 cell viability.  
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500 nM PMA was treated to MIN6 cells as a positive control. The luciferase activity was normalized to 
protein level in each set.  
Data are displayed as mean ± S.E.M (n=3). *p<0.05, **p<0.01, ***p<0.001 vs vehicle; #p<0.05, 


























Figure 2. VFE instigated intracellular Ca2+ elevation in MIN6 cells.  
(A) The representative images visualized VFE-induced intracellular Ca2+ intensity by Fura-2AM 
fluorescence ratio (ΔF340/380 nm) in MIN6 cells. The dark and crimson color indicate low and high 
[Ca2+]i,. Scale bar; 100 µm.  
(B) ΔF340/380 nm ratio at the sequential time and the area under curve of ΔF340/380 nm ratio in each 
concentration of VFE treated MIN6 cells. (n = 5-12 per group).  
(C) VFE-stimulated insulin secretion in proinsulin-Gaussia luciferase-introduced MIN6 cells in 
absence or presence of [Ca2+]e in the high glucose condition. The luciferase intensity was normalized to 
protein in each set. 
Data are presented as mean ± S.E.M (n=3). ***p<0.001 vs LG; #p<0.05, ##p<0.01, ###p<0.001 vs 







Figure 3. VFE activates PKC and MARCKS in calcium-dependent manner.  
(A-B) Western blot assay of pPKC-substrates, PKCα, and MARCKS phosphorylations followed by 
treatment of MIN6 cells with VFE in dose- (A) and time- (B) dependent manner.  
(C-D) Western blot assay (C) and insulin secretion (D) followed by treatment of MIN6 cells with VFE 
at the indicated concentrations alone or together with 10 μM Gö6983 (Gö).  
(E) VFE-stimulated insulin secretion was measured in basal or presence with 10 μM U73122 in MIN6 
cells.  
(F-G) Western blot analysis (F) and insulin secretion (G) following treatment of MIN6 cells with VFE 
at the indicated concentrations alone or together with 10 μM nifedipine (Nif).  
(H-I) Western blot analysis (H) and insulin secretion (I) following treatment of MIN6 cells with VFE 
at the indicated concentrations alone or together with 200 μM diazoxide (Diaz).  
The relative pPKCα/PKCα or pMARCKS/MARCKS ratio in all western blot analysis were quantified 
by ImageJ (AU; arbitrary unit). The luciferase activity was normalized to protein level in each set. 
Data are visualized to mean ± S.E.M (n=3). *p<0.05, **p<0.01, ***p<0.001 vs LG; #p<0.05, 
















Figure 4. VFE increases glucose uptake and promotes mitochondrial ATP production.  
(A) The effect of VFE on glucose uptake in MIN6 cells was measured by 2-NDBG-induced fluorescent 
intensity.  
(B) VFE-treated MIN6 cells were analyzed by qPCR for the gene sets expression (Glut2, PC, and INS1).  
(C) Dose-dependent CREB S133 phosphorylation by VFE in MIN6 cells.  
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(D-F) Oxygen consumption rate (D), Basal/maximum respiration (E), and ATP production (F) were 
measured after treating MIN6 cells with various concentration of VFE as indicated (n=3).  
All data are displayed as mean ± S.E.M (n=3). *p<0.05, **p<0.01, ***p<0.001 vs LG; #p<0.05, 






























Figure 5. VFE reduces blood glucose in fasted normal mice through increase insulin secretion.  
(A-B) Oral GTT test by acute VFE treatment. Right panel, AUC of OGTT (A) in NCD-supplied mice 
with non-weight difference (B). n.s.; not significant. The indicated concentrations of VFE and Glb were 
orally administrated to mice prior to 30 minutes of 3g/kg glucose oral injection.  
(C) Plasma insulin level of VFE or Glb treated NCD-fed mice. -30; the insulin measured in the blood 
collected before VFE or Glb injection, +30; the insulin measured in the blood collected after 30 min of 
glucose injection.  
Every data is presented as mean ± S.E.M (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001 vs group fed 












Figure 6. VFE improves insulin sensitivity in diabetic mice.  
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(A-B) Body weights (A) and Food intake (B) of HFD-fed mice treated with indicated concentrations of 
VFE, and Glb or vehicle for 7-weeks. n.s.; not significant.  
(C) FBG (fasting blood glucose) level of these mice after 1 week and 5 weeks. OGTT and IPITT were 
performed in HFD-fed mice treated with vehicle, VFE, and Glb. 
(D-E) The blood glucose levels and AUC of OGTT (D) and IPITT (E) were analyzed.  
(F-I) Fasting insulin (F), HOMA-IR (G), QUICKI (H), and serum TG (I) were measured in these mice.  
(J) Activation of Akt (S473 phsophorylation) and total Akt protein in both muscle and liver tissues were 
analyzed. In western blot analysis, the relative ratio of pAkt/Akt was quantified by ImageJ (AU; 
arbitrary unit).  
(K) Histological images and size of pancreatic islets were performed with Hematoxylin & Eosin (H&E) 
staining in these mice. The relative fold change of the size of islets compared to NCD-fed mice was 
quantified by ImageJ. Scale bar; 100 µm. PI; pancreatic islets, LD; intralobular duct.  
Entire results are displayed as mean ± S.E.M (n=5). *p<0.05, **p<0.01, ***p<0.001 vs NCD-fed group; 


















Fig. 7. Analysis of the major constituents of V. fordii leaves.  
(A) UPLC-QToF-MS chromatograms.  















Figure 8. The purification of 12-O-hexadecanoyl-16-hydroxyphorbol-13-acetate (HHPA) starting 











































Figure 11. The MPLC fractions of VFE screening to confirm increased insulin release in MIN6 
cells. 
(A) Analysis of insulin secretion stimulated by the 100 ng/ml VF Fr.5-derived fractions in high glucose 
condition (n=3). 
(B) Measurement of insulin secretion stimulated with the 10, 30, 50, and 100 ng/ml VF5-3 in high 
glucose condition (n=3).  
All research data are displayed as mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001 vs Vehicle; ##p<0.01 











































Figure 15. VF Fr. 5-3 subfractions screening to confirm increased insulin release in MIN6 cells. 
(A) Analysis of insulin secretion stimulated by the 30 ng/ml VF Fr.5-3-derived fractions in 16.7 mM 
glucose condition in MIN6 cells (n=3). 
(B) Analysis of insulin secretion stimulated by the indicated concentrations of VF5-3 and VF5-3-9 in 
16.7 mM glucose condition in MIN6 cells (n=3).  

























































































Figure 21. Insulinotrophic effect of HHPA from VFE in MIN6 cells. *p<0.05, **p<0.01, 










































Table 1. The UV, m/z values, MS fragments, and molecular formulae in negative ion mode for 




















Table 2. The comparison of the 1H (700 MHz) and 13C (175 MHz) data of HHPA and published 
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